Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR.

Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.

PMID:
31060979
2.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

3.

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.

Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.

4.

Targeted alpha-particle immunotherapy for acute myeloid leukemia.

Jurcic JG, Rosenblat TL.

Am Soc Clin Oncol Educ Book. 2014:e126-31. doi: 10.14694/EdBook_AM.2014.34.e126. Review.

5.

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O'Connell C, Solomon SR, Pigneux A, Vey N, Hills R, Jacobsen TF, Gianella-Borradori A, Foss Ø, Vetrhusand S, Giles FJ.

J Clin Oncol. 2014 Jun 20;32(18):1919-26. doi: 10.1200/JCO.2013.52.8562. Epub 2014 May 19.

PMID:
24841975
6.

Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram SL, Orsini JM Jr, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, Deblasio T, Jurcic JG, Nimer S, Peterson LC, Kwaan HC, Rowe JM, Douer D, Tallman MS.

Leuk Res. 2013 Sep;37(9):1004-9. doi: 10.1016/j.leukres.2013.05.007. Epub 2013 Jun 14.

PMID:
23768930
7.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

8.

Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia.

Baljevic M, Abdel-Wahab O, Rampal R, Maslak PG, Klimek VM, Rosenblat TL, Douer D, Levine RL, Tallman MS.

Acta Haematol. 2013;129(1):48-54. doi: 10.1159/000342493. Epub 2012 Nov 7.

PMID:
23147462
9.

Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions.

Rosenblat TL, Jurcic JG.

Hematol Oncol Clin North Am. 2011 Dec;25(6):1189-213. doi: 10.1016/j.hoc.2011.09.007. Review.

PMID:
22093583
10.

Emerging new approaches for the treatment of acute promyelocytic leukemia.

Park J, Jurcic JG, Rosenblat T, Tallman MS.

Ther Adv Hematol. 2011 Oct;2(5):335-52. doi: 10.1177/2040620711410773.

11.

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS.

Blood. 2011 Aug 4;118(5):1248-54. doi: 10.1182/blood-2011-04-346437. Epub 2011 Jun 8.

12.

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG.

Clin Cancer Res. 2010 Nov 1;16(21):5303-11. doi: 10.1158/1078-0432.CCR-10-0382. Epub 2010 Sep 21.

Supplemental Content

Loading ...
Support Center